- Home
- EBS vs ZNTL Comparison
EBS vs ZNTL Comparison
Compare EBS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBS | ZNTL |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.1M | 468.9M |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EBS | ZNTL |
|---|---|---|
| Price | $8.00 | $3.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.00 | $6.60 |
| AVG Volume (30 Days) | 638.8K | ★ 4.3M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.83 | 18.03 |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $742,900,000.00 | N/A |
| Revenue This Year | $1.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.71 | $1.13 |
| 52 Week High | $14.06 | $6.95 |
Technical Indicators
Market Signals| Indicator | EBS | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 52.98 |
| Support Level | $7.73 | $1.53 |
| Resistance Level | $8.54 | $6.95 |
| Average True Range (ATR) | 0.34 | 0.78 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 21.09 | 32.23 |
Price Performance
Historical ComparisonAbout EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.